Please confirm that you would like to log out of Medscape.
If you log out, you will be required to enter your username and password the next time you visit.
Log outCancel
ASCO 2021'Exciting': Olaparib Benefit Also in Early BRCA+ Breast CancerPatients taking olaparib had a 42% reduction in the risk of local recurrence of breast cancer, metastatic recurrence of breast cancer, other new cancers, or death due to any cause.
Medscape Medical News, June 3, 2021
ASCO 2021Better Cancer Survival Rates in States With Expanded MedicaidIn states that expanded Medicaid income eligibility limits, survival rates for patients with cancer were better than in states in which eligibility criteria were more restrictive.